Earnings summaries and quarterly performance for LEMAITRE VASCULAR.
Executive leadership at LEMAITRE VASCULAR.
Board of directors at LEMAITRE VASCULAR.
Research analysts who have asked questions during LEMAITRE VASCULAR earnings calls.
Brett Fishbin
KeyBanc Capital Markets
4 questions for LMAT
Daniel Stauder
Citizen JMP
4 questions for LMAT
Frank Takkinen
Lake Street Capital Markets
4 questions for LMAT
Michael Petusky
Barrington Research
4 questions for LMAT
Ross Osborn
Cantor Fitzgerald
4 questions for LMAT
James Sidoti
Sidoti & Company
3 questions for LMAT
Suraj Kalia
Oppenheimer & Co. Inc.
3 questions for LMAT
Frederick Wise
Stifel
2 questions for LMAT
Jason Wittes
Roth Capital Partners, LLC
2 questions for LMAT
Michael Sarcone
Jefferies
2 questions for LMAT
Nathan Treybeck
Wells Fargo Securities
2 questions for LMAT
Rick Wise
Stifel Financial Corp
1 question for LMAT
Shaymus Contorno
Oppenheimer & Co. Inc.
1 question for LMAT
Recent press releases and 8-K filings for LMAT.
- LeMaitre Vascular reported Q3 2025 organic sales growth of 12% and an adjusted gross margin of 70.8%. Adjusted operating income increased 29% to $16.9 million, and adjusted diluted EPS rose 27% to $0.62.
- The company updated its full-year 2025 guidance, projecting $248 million in revenue (13% growth), an adjusted gross margin of 70.3%, and adjusted operating income of $63.7 million (22% increase). Full-year adjusted diluted EPS is expected to be $2.37, up 22%.
- Product highlights include grafts sales up 23% and shunts up 18% in Q3. The international Autograft launch continues to exceed expectations, with Q3 sales of $1.4 million and an anticipated $2 million in Q4. German approval for RestorFlow was received in October, with distribution expected in Q2 2026.
- LeMaitre Vascular ended Q3 with $343.1 million in cash and securities and generated $28.8 million in cash from operations. Management indicated that while the high cash balance provides optionality, they are not relaxing their standards for acquisitions.
- The company implemented an 8% price increase for its 2026 U.S. hospital price list, with 55% of North American revenue now subject to price floors. The sales force ended Q3 with 152 reps and aims for 165 reps by year-end.
- LeMaitre Vascular reported Q3 2025 sales of $61.0 million, an 11% increase (12% organic), with adjusted diluted EPS of $0.62, up 27%.
- The company's adjusted gross margin for Q3 2025 was 70.8% and adjusted operating income was $16.9 million. Cash increased by $23.6 million sequentially to $343.1 million at the end of Q3 2025.
- LeMaitre Vascular provided Q4 2025 sales guidance of $61.8 million to $63.8 million (midpoint $62.8 million) and full-year 2025 adjusted diluted EPS guidance of $2.37.
- A quarterly dividend of $0.20 per share was announced, and the company has an ongoing share repurchase program authorized for up to $75.0 million of common stock.
Quarterly earnings call transcripts for LEMAITRE VASCULAR.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more